These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32067336)

  • 21. Sample size calculation for the augmented logrank test in randomized clinical trials.
    Hattori S; Komukai S; Friede T
    Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
    Pignatti F; Hemmings R; Jonsson B
    Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
    [No Abstract]   [Full Text] [Related]  

  • 25. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
    Kim HT; Gray R
    Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive sequential testing for multiple comparisons.
    Gao P; Liu L; Mehta C
    J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL; Stalbovskaya V; Jones B
    Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
    Zhang YY; Ting N
    J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
    Huang B; Tian L; Talukder E; Rothenberg M; Kim DH; Wei LJ
    JAMA Oncol; 2018 Jun; 4(6):874-876. PubMed ID: 29710201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical review of oncology clinical trial design under non-proportional hazards.
    Ananthakrishnan R; Green S; Previtali A; Liu R; Li D; LaValley M
    Crit Rev Oncol Hematol; 2021 Jun; 162():103350. PubMed ID: 33989767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Power and sample size calculation for the additive hazard model.
    Su PF
    J Biopharm Stat; 2017; 27(4):571-583. PubMed ID: 27294342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the importance of accounting for competing risks in pediatric brain cancer: II. Regression modeling and sample size.
    Tai BC; Grundy R; Machin D
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1139-46. PubMed ID: 20472355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
    Wu J; Xiong X
    J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time.
    Akazawa K; Nakamura T; Moriguchi S; Shimada M; Nose Y
    Comput Methods Programs Biomed; 1991 Jul; 35(3):203-12. PubMed ID: 1935013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.